Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwNHL 2018 | Novel targets and agents for lymphoma

Lymphoma treatment is focusing increasingly on novel agents with specific targets. At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2018 meeting, held in Nice, France, Laurie Sehn, MD, from the University of British Columbia, Vancouver, Canada, chaired a panel discussion on novel targets and agents in lymphoma. Targets discussed included Syk-JAK, BTK, MCL-1, BCL2, and XPO1. Demethylating agents, polatuzumab combinations, umbralisib combinations, and the optimal therapies for double-and triple-hit diffuse large B-cell lymphoma were also explored. The speakers in this discussion were John Kuruvilla, MD, FRCPC, from the Princess Margaret Cancer Centre, Toronto, Canada, and Kieron Dunleavy, MD, from George Washington University, Washington, DC.